Trial of Ixazomib for Kaposi Sarcoma

• Status: Recruiting
• Trial end date: 2025-05-31

Summary

This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

• Phase: Phase 2

Details

• Lead Sponsor: AIDS Malignancy Consortium
• Collaborator: National Cancer Institute (NCI)
• Treatments: Glycine; Ixazomib